Our in vivo work also shows that targeting HMGB1/IL-18 signaling rescues muscle-specific differentiation marker expression in glycerol-induced muscle injury, which indicates that targeting IL-18 is worthwhile for the treatment of skeletal muscle atrophy. The gene discussed is HMGB1; the disease is muscle atrophy.